Benzinga | Jan 11, 2021 12:34PM EST

Boston Scientific Corp Says FDA Recall Decision Expected To Be Accretive For Co's GAAP, Adj. EPS In 2021 By About One To Two Cents, Neutral Thereafter

-Reuters